Protective effect of high-mobility group box 1 blockade on acute liver failure in rats

Shock

Volumn 34, Issue 6, 2010, Pages 573-579

  Takano, Kiminori ^a   Shinoda, Masahiro ^a   Tanabe, Minoru ^a   Miyasho, Taku ^b   Yamada, Shingo ^c   Ono, Shigeshi ^a   Masugi, Yohei ^a   Suda, Koichi ^a   Fukunaga, Koichi ^a   Hayashida, Tetsu ^a   Hibi, Taizo ^a   Obara, Hideaki ^a   Takeuchi, Hiroya ^a   Kawachi, Shigeyuki ^a   Kawasako, Kazufumi ^b   Okamoto, Minoru ^b   Yokota, Hiroshi ^b   Maruyama, Ikuro ^d   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RAKUNO GAKUEN UNIVERSITY   (Japan)

^c SHINO TEST CORPORATION   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Acute liver failure; antibody; high mobility group box 1; necrosis; rat model

Indexed keywords

GALACTOSAMINE; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; INTERLEUKIN 6; LIVER ENZYME; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LIVER FAILURE; MALE; NONHUMAN; PENILE BLOOD VESSEL; RAT; SPRAGUE DAWLEY RAT; SURVIVAL;

ANIMALS; ANTIBODIES; CHICKENS; FEMALE; HMGB1 PROTEIN; IMMUNOHISTOCHEMISTRY; LIVER; LIVER FAILURE, ACUTE; MALE; RATS; RATS, SPRAGUE-DAWLEY; SWINE;

EID: 78649535273     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181df0433     Document Type: Article

References (28)

1. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borvikova L, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251, 1999.
2. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Harris HE, Janson A, Kokkola R, Zhang M, Yang H, et al.: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565-570, 2000.
3. Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M, Bianchi ME: New EMBO members' review: the double life of HMGB1 chroma-tin protein: architectural factor and extracellular signal. EMBO J 20:4337-4340, 2001.
4. Zhang F, He Y, Duan Z: Changes of high-mobility group box 1 in serum of pig acute hepatic failure model and significance. J Huazhong Univ Sci Technolog Med Sci 28:52-55, 2008.
5. Jensenius JC, Andersen I, Hau J, Crone M, Koch C: Eggs: conveniently packaged antibodies. Methods for purification of yolk IgG. J Immunol Methods 46:63-68, 1981.
6. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, et al.: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 115:1267-1274, 2005.
7. Yamada S, Inoue K, Yakabe K, Imaizumi H, Maruyama I: High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 49:1535-1537, 2003.
8. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ: HMG-1 as a mediator of acute lung inflammation. J Immunol 165:2950-2954, 2000.
9. Watanabe T, Kubota S, Nagaya M, Ozaki S, Nagafuchi H, Akashi K, Taira Y, Tsukikawa S, Oowada S, Nakano S: The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J Surg Res 124:59-66, 2005.
10. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, et al.: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201:1135-1143, 2005.
11. Suda K, Kitagawa Y, Ozawa S, Saikawa Y, Ueda M, Ebina M, Yamada S, Hashimoto S, Fukata S, Abraham E, et al.: Anti-high mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 30:1755-1762, 2006.
12. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, et al.: High mobility group box 1 in ischemia-reperfusion injury of the heart. Circulation 117:3216-3226, 2008.
13. Yuan H, Jin X, Sun J, Li F, Feng Q, Zhang C, Cao Y, Wang Y: Protective effect of HMGB1 a box on organ injury of acute pancreatitis in mice. Pancreas 38:143-148, 2009.
14. Shinoda M, Tilles AW, Kobayashi N, Wakabayashi G, Takayanagi A, Totsugawa T, Harada H, Obara H, Suganuma K, Berthiaume F, et al.: A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats. J Surg Res 137:130-140, 2007.
15. Shinoda M, Tilles AW, Wakabayashi G, Takayanagi A, Harada H, Obara H, Suganuma K, Berthiaume F, Shimazu M, Shimizu N, et al.: Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist. Tissue Eng 12:1313-1323, 2006.
16. Shito M, Balis UJ, Tompkins RG, Yarmush ML, Toner M: A fulminant hepatic failure model in the rat: involvement of interleukin-1beta and tumor necrosis factor-alpha. Dig Dis Sci 46:1700-1708, 2001.
17. Sekiyama KD, Yoshiba M, Thomson AW: Circulating proinflammatory cyto-kines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 98:71-77, 1994.
18. Shinoda M, Wakabayashi G, Shimazu M, Saito H, Hoshino K, Tanabe M, Morikawa Y, Endo S, Ishii H, Kitajima M: Increased serum and hepatic tissue levels of interleukin-18 in patients with fulminant hepatic failure. J Gastro-enterol Hepatol 21:1731-1736, 2006.
19. Müller S, Ronfani L, Bianchi ME: Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255:332-343, 2004.
20. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195, 2002.
21. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H: Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic re-combinant HMGB1 (amphoterin). J Leukoc Biol 81:49-58, 2007.
22. Sha Y, Zmijewski J, Xu Z, Abraham E: HMGB1 develops enhanced proin-flammatory activity by binding to cytokines. J Immunol 180:2531-2537, 2008.
23. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, et al.: Toll-like receptor 9Ydependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8:487-496, 2007.
24. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, Sitia G, Yap GS, Wan Y, Biron CA, et al.: A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110:1970-1981, 2007.
25. Cassetta L, Fortunato O, Adduce L, Rizzi C, Hering J, Rovere-Querini P, Bianchi ME, Alfano M, Poli G: Extracellular HMGB1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines. AIDS 23:567-577, 2009.
26. Bianchi ME: HMGB1 loves company. J Leukoc Biol 86:573-576, 2009.
27. Dejager L, Libert C: Tumor necrosis factor alpha mediates the lethal hepa-totoxic effects of poly(I:C) in D-galactosamineYsensitized mice. Cytokine 42:55-61, 2008.
28. Josephs MD, Bahjat FR, Fukuzuka K, Ksontini R, Solorzano CC, Edwards CK 3rd, Tannahill CL, MacKay SL, Copeland EM 3rd, Moldawer LL: Lipo-polysaccharide and D-galactosamineYinduced hepatic injury is mediated by TNF-alpha and not by Fas ligand. Am J Physiol Regul Integr Comp Physiol 278:R1196-R1201, 2000.